Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
7-day vs 14-day Antibiotics for Neonatal Sepsis
NCT03280147Phase 3Completed
- Sponsor
- Indian Council of Medical Research
- Start
- Jan 2019
- Primary completion
- Jan 2023
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in neonatal sepsis (2 arms), sponsored by Indian Council of Medical Research. Primary endpoint: Definite or probable relapse within 21 days post-antibiotic completion. Started Jan 2019; status: completed.
02
Conditions
neonatal sepsis
Beyond the preview
Go deeper on NCT03280147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03280147.